Belinsky S A, Kauffman F C, Sokolove P M, Tsukuda T, Thurman R G
J Biol Chem. 1984 Jun 25;259(12):7705-11.
Rates of production of p-nitrophenyl glucuronide by isolated perfused livers from fed or fasted phenobarbital-treated rats were estimated by monitoring the concentration of glucuronide in the effluent perfusate. Infusion of epinephrine decreased the steady state level of p-nitrophenyl glucuronide by about 39% (half-maximal inhibition at approximately 5 microM). This result was unexpected because epinephrine activated glycogenolysis and elevated hepatic UDP-glucuronic acid contents. The effect of epinephrine can be attributed to its interaction with alpha-adrenergic receptors, since the inhibition of glucuronide production by epinephrine was reversed by an alpha-antagonist (phentolamine) but not by a beta-antagonist, propranolol. Since alpha-adrenergic agonists increase the cytosolic free calcium concentration, we investigated the possibility that the decrease in glucuronide production elicited by epinephrine was mediated by calcium. Removal of calcium from the perfusion fluid diminished the inhibition of glucuronide production by epinephrine, while increasing extracellular calcium from 0 to 150 microM restored the inhibition in a dose-dependent manner. In the presence of extracellular calcium, glucuronide production was inhibited by the addition of the calcium ionophore A23187 or angiotensin II, a hormone which increases cytosolic calcium. Concentrations of ionized calcium comparable to physiological intracellular levels (0.1-2 microM) increased microsomal beta-glucuronidase activity by 50 to 100% but had no effect on microsomal glucuronosyl-transferases . These results indicate that activation of hepatic alpha-adrenergic receptors increases cytosolic calcium which stimulates microsomal beta-glucuronidase activity. This decreases net glucuronide formation by the liver. In support of this hypothesis, rates of glucuronide production were unaffected by epinephrine in perfused livers from beta-glucuronidase-deficient C3H/HeJ mice.
通过监测流出灌注液中葡糖醛酸苷的浓度,估算了来自喂食或禁食的苯巴比妥处理大鼠的离体灌注肝脏产生对硝基苯基葡糖醛酸苷的速率。肾上腺素的输注使对硝基苯基葡糖醛酸苷的稳态水平降低了约39%(在约5微摩尔时达到半数最大抑制)。这一结果出乎意料,因为肾上腺素激活了糖原分解并提高了肝脏尿苷二磷酸葡糖醛酸的含量。肾上腺素的作用可归因于其与α-肾上腺素能受体的相互作用,因为肾上腺素对葡糖醛酸苷产生的抑制作用可被α-拮抗剂(酚妥拉明)逆转,但不能被β-拮抗剂普萘洛尔逆转。由于α-肾上腺素能激动剂会增加胞质游离钙浓度,我们研究了肾上腺素引起的葡糖醛酸苷产生减少是否由钙介导的可能性。从灌注液中去除钙可减少肾上腺素对葡糖醛酸苷产生的抑制作用,而将细胞外钙从0增加到150微摩尔则以剂量依赖的方式恢复了抑制作用。在存在细胞外钙的情况下,添加钙离子载体A23187或血管紧张素II(一种增加胞质钙的激素)会抑制葡糖醛酸苷的产生。与生理细胞内水平相当的离子钙浓度(0.1 - 2微摩尔)使微粒体β-葡糖醛酸酶活性增加了50%至100%,但对微粒体葡糖醛酸基转移酶没有影响。这些结果表明,肝脏α-肾上腺素能受体的激活会增加胞质钙,从而刺激微粒体β-葡糖醛酸酶活性。这会减少肝脏中葡糖醛酸苷的净形成。为支持这一假设,在来自β-葡糖醛酸酶缺陷的C3H/HeJ小鼠的灌注肝脏中,肾上腺素对葡糖醛酸苷产生的速率没有影响。